{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:30:39Z","timestamp":1790958639672,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.intimp.2019.05.047","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T16:16:01Z","timestamp":1560788161000},"page":"105662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs half-life and enhances antitumor effects in vivo"],"prefix":"10.1016","volume":"74","author":[{"given":"Xutong","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caoying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renhao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhen","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.intimp.2019.05.047_bb0005","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nbt.3040","article-title":"Biopharmaceutical benchmarks 2014","volume":"32","author":"Walsh","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.intimp.2019.05.047_bb0010","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/cpt.275","article-title":"Microdosing of protein drugs","volume":"99","author":"Rowland","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"issue":"19","key":"10.1016\/j.intimp.2019.05.047_bb0015","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1073\/pnas.1408766112","article-title":"Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics","volume":"112","author":"Schoch","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.intimp.2019.05.047_bb0020","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1091\/mbc.e04-08-0735","article-title":"From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling","volume":"16","author":"Ward","year":"2005","journal-title":"Mol. Biol. Cell"},{"issue":"30","key":"10.1016\/j.intimp.2019.05.047_bb0025","doi-asserted-by":"crossref","first-page":"11076","DOI":"10.1073\/pnas.0402970101","article-title":"Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level","volume":"101","author":"Ober","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.intimp.2019.05.047_bb0030","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1091\/mbc.e07-02-0101","article-title":"Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells","volume":"19","author":"Goebl","year":"2008","journal-title":"Mol. Biol. Cell"},{"issue":"12","key":"10.1016\/j.intimp.2019.05.047_bb0035","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/ijc.31945","article-title":"exSSSRs (extracellular S100 Soil Sensor Receptors)-Fc fusion proteins work as prominent decoys to S100A8\/A9-induced lung tropic cancer metastasis.%A Kinoshita R","volume":"144","author":"H","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2019.05.047_bb0040","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2009-08-239665","article-title":"Prolonged activity of factor IX as a monomeric fc fusion protein","volume":"115","author":"Peters","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.intimp.2019.05.047_bb0045","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.4049\/jimmunol.1701666","article-title":"Human factor H domains 6 and 7 fused to IgG1 Fc are immunotherapeutic against Neisseria gonorrhoeae","volume":"201","author":"Shaughnessy","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2019.05.047_bb0050","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fimmu.2014.00146","article-title":"Interactions of IgG1 CH2 and CH3 domains with FcRn","volume":"5","author":"Ying","year":"2014","journal-title":"Front. Immunol."},{"issue":"35","key":"10.1016\/j.intimp.2019.05.047_bb0055","doi-asserted-by":"crossref","first-page":"25154","DOI":"10.1074\/jbc.M113.484154","article-title":"Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics","volume":"288","author":"Ying","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2019.05.047_bb0060","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1073\/pnas.56.3.1010","article-title":"Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin)","volume":"56","author":"Goldstein","year":"1966","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2019.05.047_bb0065","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1517\/14712598.2015.1044895","article-title":"Thymosin alpha1: burying secrets in the thymus","volume":"15","author":"Moretti","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2019.05.047_bb0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2013.05.006","article-title":"The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin alpha1-thymopentin fusion peptide and its binding to TLR2","volume":"337","author":"Li","year":"2013","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.intimp.2019.05.047_bb0075","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s12264-017-0162-x","article-title":"Immunopotentiator thymosin Alpha-1 promotes neurogenesis and cognition in the developing mouse via a systemic Th1 bias","volume":"33","author":"Wang","year":"2017","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.intimp.2019.05.047_bb0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/fmb-2016-0125","article-title":"Thymosin alpha 1 and HIV-1: recent advances and future perspectives","volume":"12","author":"Matteucci","year":"2017","journal-title":"Future Microbiol"},{"issue":"5","key":"10.1016\/j.intimp.2019.05.047_bb0085","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0196-9781(02)00025-6","article-title":"Thymosin alpha(1) inhibits mammary carcinogenesis in Fisher rats","volume":"23","author":"Moody","year":"2002","journal-title":"Peptides"},{"issue":"21","key":"10.1016\/j.intimp.2019.05.047_bb0090","first-page":"5214","article-title":"Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo","volume":"53","author":"Moody","year":"1993","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2019.05.047_bb0095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00008390-200010020-00012","article-title":"Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma","volume":"10","author":"Rasi","year":"2000","journal-title":"Melanoma Res."},{"issue":"10","key":"10.1016\/j.intimp.2019.05.047_bb0100","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.2009.25.5208","article-title":"Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma","volume":"28","author":"Maio","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2019.05.047_bb0105","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1517\/17425247.2015.961420","article-title":"Long-term delivery of protein therapeutics","volume":"12","author":"Vaishya","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"5","key":"10.1016\/j.intimp.2019.05.047_bb0110","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nm.4305","article-title":"Thymosin alpha 1 represents a potential potent single-molecule-based therapy for cystic fibrosis","volume":"23","author":"Romani","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2019.05.047_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2010.05465.x","article-title":"Thymosin alpha1: the regulator of regulators?","volume":"1194","author":"Pierluigi","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2019.05.047_bb0120","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"33","key":"10.1016\/j.intimp.2019.05.047_bb0125","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall\u2019Acqua","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.intimp.2019.05.047_bb0130","doi-asserted-by":"crossref","first-page":"7663","DOI":"10.4049\/jimmunol.0804182","article-title":"Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates","volume":"182","author":"Yeung","year":"2009","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2019.05.047_bb0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.intimp.2019.05.047_bb0140","first-page":"S69","article-title":"Thymalfasin: an immune system enhancer for the treatment of liver disease","volume":"19","author":"Sjogren","year":"2004","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2019.05.047_bb0145","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.biopha.2018.09.064","article-title":"Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo","volume":"108","author":"Shen","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.intimp.2019.05.047_bb0150","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00262-010-0862-9","article-title":"Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris","volume":"59","author":"Chen","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"2 Pt B","key":"10.1016\/j.intimp.2019.05.047_bb0155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.canlet.2014.10.002","article-title":"Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression","volume":"356","author":"Ni","year":"2015","journal-title":"Cancer Lett."},{"issue":"sup1","key":"10.1016\/j.intimp.2019.05.047_bb0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1517\/14712598.2015.1008446","article-title":"Evaluation of thymosin \u03b1 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis","volume":"15","author":"King","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2019.05.047_bb0165","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/302084","article-title":"Potential role of thymosin-alpha1 adjuvant therapy for glioblastoma","volume":"2009","author":"Sungarian","year":"2009","journal-title":"J. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2019.05.047_bb0170","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.4049\/jimmunol.1400656","article-title":"Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by mycobacterium tuberculosis heat shock protein X","volume":"193","author":"Jung","year":"2014","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2019.05.047_bb0175","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s00268-004-7817-2","article-title":"Roles of thymosins in cancers and other organ systems","volume":"29","author":"Chen","year":"2005","journal-title":"World J. Surg."},{"issue":"9","key":"10.1016\/j.intimp.2019.05.047_bb0180","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.celrep.2016.10.086","article-title":"Tailored tumor immunogenicity reveals regulation of CD4 and CD8 T cell responses against cancer","volume":"17","author":"Knocke","year":"2016","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.intimp.2019.05.047_bb0185","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00262-016-1823-8","article-title":"Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice","volume":"65","author":"Contreras","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2019.05.047_bb0190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1749-6632.2012.06697.x","article-title":"Thymosin \u03b11 and cancer: action on immune effector and tumor target cells.%A Garaci E","volume":"1269","author":"F","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919302061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919302061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:17:20Z","timestamp":1761585440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919302061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":38,"alternative-id":["S1567576919302061"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.05.047","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs half-life and enhances antitumor effects in vivo","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.05.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105662"}}